We’re proud to once again be ranked in the top five of Americas Most Just companies in biopharma. The honor reflects our ongoing commitment to operate responsibly and empower our employees to help create a healthier world for all.
In recognition of Women's History Month, our Identity + Innovation spotlight features Devi SenGupta. Hear how Devi's background has shaped her approach to developing new medicines and to bringing Gilead closer to a cure for HIV.
Lauren Huffmaster received a late-stage metastatic breast cancer (mBC) diagnosis in 2015 and soon discovered there wasn’t a lot information to help explain to her young children what she was going through.
Each scientific discovery gets us one step closer to our shared goal of ending the HIV epidemic. As a leader in HIV treatment and prevention, we’ll continue to build on our legacy and create innovative solutions to address the diverse needs of all people affected by HIV.
As a nation where 90% of all people living with HIV know their diagnosis and are being treated, Germany has made great strides to advance its HIV care goals.
Gilead scientists had planned for a moment like this through years of research. When coronaviruses with pandemic potential, like SARS and MERS, emerged in the early 2000s, Gilead began searching for potential new antivirals.
This Earth Day, we’re highlighting our longstanding commitment to environmental stewardship. We’ll continue to accelerate our efforts to reduce greenhouse gas emissions, minimize waste generation and operate responsibly.
If left untreated, VL kills 95% of its victims. Though progress has been made, we still have a way to go and, as we look to the next decade, eliminating VL will continue to be a priority for Gilead Sciences.
The deficit of Black male teachers in the United States is profound. According to the U.S. Department of Education, Black men comprise just 2% of all teachers. The Man the Bay fellowship offers a multi-pronged solution.
“In 2005, I began dreaming about starting a trans-led, immigrant-led organization,” she says. “My dream came true two years later when I started the nonprofit.”
Anu Osinusi recently spoke with us about how hepatitis research and treatment have changed over her career, why HDV is considered the “forgotten virus” and what’s next for Gilead.
Gilead’s Corporate Social Responsibility (CSR) Report provides an overview of the work the company is doing around the world to improve the lives of...